Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Conditions
Keywords
PARP Inhibitor, BRCA Mutations, DNA Damage Repair, Pharmacodynamics, Metronomic Cyclophosphamide, Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Brief summary
Background: \- The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells. Cyclophosphamide is a cancer treatment drug that works by causing DNA damage in cells, including cancer cells, resulting in cell death. However, because cyclophosphamide has strong and unpleasant side effects, researchers are interested in finding drugs that can be given in combination with cyclophosphamide that will allow a lower dose of cyclophosphamide to be given with similar effects. The combination of ABT-88 and cyclophosphamide may be an effective treatment for some types of cancer, such as certain kinds of breast or ovarian cancer and non-Hodgkin's lymphoma that often do not respond to standard therapies. Objectives: \- To evaluate the safety and effectiveness of ABT-888 and cyclophosphamide in ovarian and breast cancer and in non-Hodgkin's lymphoma that have not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have been diagnosed with (1) (Breast cancer 1/2) BRCA1/2 ovarian cancer, primary peritoneal or ovarian high-grade carcinoma, or fallopian tube cancer; (2) triple-negative breast cancer (not responsive to hormone-related therapy); or (3) low grade non-Hodgkin's lymphoma. Design: * Participants will be screened with a full medical history and physical examination, blood and urine tests, and tumor imaging studies. Participants will be divided into two groups with different treatment subgroups. * Group 1: Participants who have BRCA-positive ovarian cancer, primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer * Participants will receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone. * Participants will take the study drug by mouth once a day for 21-day cycles of treatment, and will keep a diary to record drug doses and any side effects. * Participants will have clinic visits with blood and urine tests, imaging studies, and other examinations on days 1, 2, 7, and 14 of cycle 1, and on the first day of all other cycles. * Group 2: Participants who have triple-negative breast cancer or non-Hodgkin's lymphoma * Participants will receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone. * Participants will take the study drug by mouth once a day for 21-day cycles of treatment, and will keep a diary to record drug doses and any side effects. * Participants will have clinic visits with blood and urine tests, imaging studies, and other examinations on days 1, 2, 7, and 14 of cycle 1, and on the first day of all other cycles. * Participants receiving only cyclophosphamide who show signs of disease progression after tumor imaging studies can receive the combination of ABT-888 with cyclophosphamide. * Treatment will continue as long as participants tolerate the drugs and the disease does not progress.
Detailed description
Background: * The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. * Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. * Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity. Objectives: * Compare the response rate (complete response (CR) + partial response (PR)) of the combination of ABT-888 with metronomic oral cyclophosphamide to the response rate (CR+PR) of metronomic oral cyclophosphamide in patients with deleterious BRCA mutations and refractory ovarian cancer or patients with primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer. * Compare the response rate (CR+PR) of the combination of ABT-888 with metronomic oral cyclophosphamide to the response rate (CR+PR) of single-agent oral cyclophosphamide in patients with triple-negative metastatic breast cancer, stratified for deleterious BRCA mutation. * Compare the response rate (CR+PR) of the combination of ABT-888 with metronomic oral cyclophosphamide to the response rate (CR+PR) of single-agent metronomic oral cyclophosphamide in patients with refractory low-grade lymphomas. Secondary Objectives: \- Determine PAR levels in tumor biopsies, evaluate in archival tissue whether patients tumors have mutations in genes involved in DNA damage repair (e.g., BRCA/Fanconi anemia/protein 53 (p53)), perform exploratory gene expression profiling to correlate PARP messenger ribonucleic acid (mRNA) levels or BRCA mutation status with response to therapy, count circulating tumor cells (CTCs), and determine H2AX levels in CTCs and tumor biopsies (National Cancer Institute (NCI) clinical center only). Eligibility: -Adults with refractory BRCA-positive ovarian cancer, primary peritoneal or ovarian high-grade serous carcinoma, fallopian tube cancer, triple-negative breast cancer, or low-grade lymphoid malignancies (non-Hodgkin's lymphoma) whose disease has progressed following at least one line of therapy. Study Design: * This is a randomized, multi-histology Phase II trial with patients enrolled into 3 cohorts: BRCA-positive ovarian cancer or primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (A); triple-negative breast cancer (B); or low grade non-Hodgkin's lymphoma (C). Patients in cohort A will be randomized to the combination of ABT-888 with metronomic oral cyclophosphamide or metronomic oral cyclophosphamide alone. Patients in cohort B will be randomized to the combination of ABT-888 with metronomic oral cyclophosphamide or metronomic oral cyclophosphamide alone. Patients in cohort C will be randomized to the combination of ABT-888 with metronomic oral cyclophosphamide or metronomic oral cyclophosphamide alone. * Cyclophosphamide (50 mg) and ABT-888 (60 mg) will be administered orally once a day, continuously in 21-day cycles.
Interventions
DRUGABT-888
PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
DRUGCyclophosphamide
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: * Patients with histologically documented: * BRCA-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score of greater than or equal to 30%) * primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer (no requirement for BRCA status) * triple-negative breast cancer (documented estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (Her2/neu) negative from the original pathology report if considered adequate, or per The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (47, 48)) with metastasis to distant sites * Low-grade lymphoid malignancies (NHL), as described below, whose disease has progressed following at least one line of standard therapy: * Follicle center lymphoma, follicular or diffuse-recurrent/refractory * Marginal zone B-cell lymphoma: splenic, nodal, extranodal (this includes mucosa-associated lymphoid tissue (MALT)) - recurrent/refractory * Lymphoplasmacytic lymphoma - recurrent/refractory * Small lymphocytic lymphoma (SLL) (absolute lymphocytes count below 5,000) Pathology must be confirmed by the registering institution. For patients who are eligible for the study due to a history of BRCA1/2 mutation, documented evidence of their mutation status must be provided prior to enrolling on the study. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT) scan. * Any prior therapy or radiotherapy must have been completed greater than or equal to 4 weeks (greater than 6 weeks for nitrosoureas or mitomycin C) prior to enrollment on protocol, and the participant must have recovered to eligibility levels from prior toxicity. Patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study, and should have recovered to eligibility levels from any toxicities. * Patients who have had prior treatment with any PARP inhibitors are eligible unless the PARP inhibitor was administered in combination with cyclophosphamide. * Patients with bone metastases or hypercalcemia on bisphosphonate treatment are eligible to participate * Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of ABT-888 in patients less than 18 years of age, children are excluded from this study, but may be eligible for future pediatric Phase I combination trials. * Karnofsky performance status greater than or equal to 70%. * Life expectancy greater than 3 months. * Patients must have adequate organ and marrow function as defined below: * absolute neutrophil count greater than or equal to 1,500/microL (mcL) * platelets greater than or equal to 100,000/microL (mcL) * total bilirubin less than 1.5 times institutional upper limit of normal * Aspartate aminotransaminase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransaminase (ALT) serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5 times institutional upper limit of normal * creatinine less than 1.5 times institutional upper limit of normal OR --creatinine clearance greater than or equal to 60 mL/min for patients with creatinine levels greater than or equal to 1.5 times institutional upper limit of normal. * The effects of ABT-888 on the developing human fetus are unknown. For this reason and because cyclophosphamide hydrochloride is known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (abstinence; female use of hormonal methods, or barrier methods of birth control; male use of a condom) prior to study entry, for the duration of study participation, and for 3 months after completion of study. Because there is a risk for adverse events in nursing infants secondary to treatment of the mother with cyclophosphamide, breastfeeding should be discontinued while the patient is on this trial and for 30 days after completion of treatment on this trial. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Women who are pregnant or breastfeeding. * Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients with germ cell and borderline ovarian epithelial tumors. * Patients who have received prior cyclophosphamide should not be excluded solely because of receiving prior cyclophosphamide. * Patients with history of central nervous system (CNS) metastases who have received treatment and who have been on stable doses of anti-seizure medicine and had no seizures x 3 months will be eligible. * Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow the capsule whole. Capsules must not be crushed or chewed; nasogastric or gastrostomy tube (G-tube) administration is not allowed. INCLUSION OF WOMEN AND MINORITIES: -Men and women of all races and ethnic groups are eligible for this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With an Overall Response Rate | an average of 126 days for ovarian; 71 days for TNBC; for crossover intervention, pts stayed on study for an avg of 134 days for ovarian; 50 days for TNBC. | Complete response (CR) + partial response (PR)) of the combination of ABT-888 with metronomic oral cyclophosphamide to the response rate (CR+PR) of metronomic oral cyclophosphamide in patients with deleterious BRCA mutations and refractory ovarian cancer or patients with primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer. CR + PR was determined by the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm). Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Progression Free Survival | Ovarian cancer patients stayed on study for an average of 126 days and triple-negative breast cancer patients for an average of 71 days. | Time to progression for each participant for the initial intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | up to 30 days following the last dose of study drug. | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. |
| Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline | At baseline (t=0h) and 4h post drug administration (t=4h) | PAR levels (in pg/μg protein) were assessed in peripheral blood mononuclear cells (PBMCs) by immunoassay to assess poly (ADP-ribose) polymerase (PARP) activity. Significant inhibition of PARP activity is associated with 50% or greater reduction in PAR levels. |
| Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood | At baseline (t=0h) and 24h post drug administration (t=24h) | Number of CTCs (evaluable defined as ≥ 6 CTCs) were measured in whole blood during the course of treatment to determine drug-induced deoxyribonucleic acid damage in tumor cells. |
| Number of Participants With Deleterious Mutations in DNA Repair Genes | Optional tumor biopsies were performed prior to start of treatment (baseline) and 6 months | Gene expression profiling was performed in archival tumor tissue for a panel of 211 genes using deoxyribonucleic acid (DNA) array to determine deleterious mutations (i.e. nonsynonymous mutations at coding regions) of genes. Sequences were mapped to human genome reference hg19. Variants were identified with VarScan, annotated with AVIA, and masked to the exonic or exonic:splicing regions of the 211 interrogated DNA repair genes, with nonsynonymous/frameshift/stop-gain/stop-loss variants that have a population frequency of 1% or less in either 1000G (2014\_04) or the ExomeSequencingProject (ESP6500si\_all) with a minimum variant frequency of 10% and at least 20 reads. Lastly, variants were manually inspected for known platform and mapping errors. |
Countries
Canada, United States
Participant flow
Pre-assignment details
Triple-negative breast cancer participants were enrolled but three did not start the study (two withdrew, 1 progressed).
Participants by arm
| Arm | Count |
|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO). | 25 |
| Triple-negative Breast Cancer: Cyclophosphamide Alone Oral cyclophosphamide 50mg by mouth (PO) for 21 days. | 20 |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO). | 37 |
| BRCA-positive Ovarian Cancer: Cyclophosphamide Alone Oral cyclophosphamide 50mg by mouth (PO) for 21 days. | 38 |
| Non-Hodgkin's: ABT-888 + Cyclophosphamide Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO). | 2 |
| Non-Hodgkin's: Cyclophosphamide Alone Oral cyclophosphamide 50mg by mouth (PO) for 21 days. | 2 |
| Total | 124 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Disease Progression/Crossover | other/symptomatic progression | 0 | 2 | 0 | 2 | 0 | 0 |
| Disease Progression/Crossover | Withdrawal by Subject | 0 | 0 | 0 | 1 | 0 | 0 |
| First Intervention | Adverse Event | 1 | 0 | 1 | 0 | 0 | 1 |
| First Intervention | Death | 0 | 0 | 1 | 0 | 0 | 0 |
| First Intervention | Ineligible | 0 | 0 | 0 | 0 | 0 | 1 |
| First Intervention | Progressive disease | 0 | 0 | 0 | 0 | 2 | 0 |
| First Intervention | Withdrawal by Subject | 0 | 2 | 0 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Triple-negative Breast Cancer: Cyclophosphamide Alone | BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | BRCA-positive Ovarian Cancer: Cyclophosphamide Alone | Non-Hodgkin's: ABT-888 + Cyclophosphamide | Non-Hodgkin's: Cyclophosphamide Alone | Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Total |
|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 4 Participants | 9 Participants | 9 Participants | 1 Participants | 0 Participants | 5 Participants | 28 Participants |
| Age, Categorical Between 18 and 65 years | 16 Participants | 28 Participants | 29 Participants | 1 Participants | 2 Participants | 20 Participants | 96 Participants |
| Age, Continuous | 53 years STANDARD_DEVIATION 13 | 57 years STANDARD_DEVIATION 10 | 58 years STANDARD_DEVIATION 10 | 70 years STANDARD_DEVIATION 24 | 56 years STANDARD_DEVIATION 6 | 55 years STANDARD_DEVIATION 10 | 57 years STANDARD_DEVIATION 11 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants | 36 Participants | 35 Participants | 1 Participants | 2 Participants | 22 Participants | 113 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 2 Participants | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 7 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 15 Participants | 35 Participants | 37 Participants | 2 Participants | 2 Participants | 16 Participants | 107 Participants |
| Region of Enrollment Canada | 3 Participants | 14 Participants | 15 Participants | 0 Participants | 0 Participants | 3 Participants | 35 Participants |
| Region of Enrollment United States | 17 Participants | 23 Participants | 23 Participants | 2 Participants | 2 Participants | 22 Participants | 89 Participants |
| Sex: Female, Male Female | 20 Participants | 37 Participants | 38 Participants | 1 Participants | 2 Participants | 25 Participants | 123 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 37 | 0 / 38 | 0 / 29 | 0 / 21 | 0 / 18 | 0 / 16 | 0 / 2 | 0 / 1 |
| other Total, other adverse events | 28 / 37 | 24 / 38 | 29 / 29 | 14 / 21 | 4 / 18 | 6 / 16 | 0 / 2 | 1 / 1 |
| serious Total, serious adverse events | 3 / 37 | 0 / 38 | 0 / 29 | 2 / 21 | 0 / 18 | 1 / 16 | 0 / 2 | 1 / 1 |
Outcome results
Primary
Percentage of Participants With an Overall Response Rate
Complete response (CR) + partial response (PR)) of the combination of ABT-888 with metronomic oral cyclophosphamide to the response rate (CR+PR) of metronomic oral cyclophosphamide in patients with deleterious BRCA mutations and refractory ovarian cancer or patients with primary peritoneal or ovarian high-grade serous carcinoma or fallopian tube cancer. CR + PR was determined by the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm). Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: an average of 126 days for ovarian; 71 days for TNBC; for crossover intervention, pts stayed on study for an avg of 134 days for ovarian; 50 days for TNBC.
Population: Participants evaluable for response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Percentage of Participants With an Overall Response Rate | 9.5 percentage of participants |
| Triple-negative Breast Cancer: Cyclophosphamide Alone | Percentage of Participants With an Overall Response Rate | 5.6 percentage of participants |
| Triple-negative Breast Cancer: Crossover | Percentage of Participants With an Overall Response Rate | 0 percentage of participants |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | Percentage of Participants With an Overall Response Rate | 11.8 percentage of participants |
| BRCA-positive Ovarian Cancer: Cyclophosphamide Alone | Percentage of Participants With an Overall Response Rate | 19.4 percentage of participants |
| BRCA-positive Ovarian Cancer: Crossover | Percentage of Participants With an Overall Response Rate | 3.4 percentage of participants |
Primary
Progression Free Survival
Time to progression for each participant for the initial intervention.
Time frame: Ovarian cancer patients stayed on study for an average of 126 days and triple-negative breast cancer patients for an average of 71 days.
Population: Participants evaluable for response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Progression Free Survival | 3 Cycles of therapy |
| Triple-negative Breast Cancer: Cyclophosphamide Alone | Progression Free Survival | 2 Cycles of therapy |
| Triple-negative Breast Cancer: Crossover | Progression Free Survival | 3 Cycles of therapy |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | Progression Free Survival | 3 Cycles of therapy |
p-value: 0.034Log Rank
p-value: 0.68Log Rank
Secondary
Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline
PAR levels (in pg/μg protein) were assessed in peripheral blood mononuclear cells (PBMCs) by immunoassay to assess poly (ADP-ribose) polymerase (PARP) activity. Significant inhibition of PARP activity is associated with 50% or greater reduction in PAR levels.
Time frame: At baseline (t=0h) and 4h post drug administration (t=4h)
Population: Patients with PBMCs data pre- and post-drug administration, and with PAR levels above the lower limit of quantitation (LLOQ) of 23 pg/μg protein were analyzed.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline | -81 pg/μg protein |
| Triple-negative Breast Cancer: Crossover | Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline | -88 pg/μg protein |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline | -74 pg/μg protein |
| BRCA-positive Ovarian Cancer: Crossover | Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline | -85 pg/μg protein |
Secondary
Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood
Number of CTCs (evaluable defined as ≥ 6 CTCs) were measured in whole blood during the course of treatment to determine drug-induced deoxyribonucleic acid damage in tumor cells.
Time frame: At baseline (t=0h) and 24h post drug administration (t=24h)
Population: Patients with sufficient CTC counts (defined as ≥6 total CTCs) pre- and post-drug administration were analyzed.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Triple-negative Breast Cancer: Crossover | Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood | 400 ϓH2AX- Positive CTCs |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood | 200 ϓH2AX- Positive CTCs |
| BRCA-positive Ovarian Cancer: Crossover | Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood | 9.5 ϓH2AX- Positive CTCs |
Secondary
Number of Participants With Adverse Events
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.
Time frame: up to 30 days following the last dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Number of Participants With Adverse Events | 28 Participants |
| Triple-negative Breast Cancer: Cyclophosphamide Alone | Number of Participants With Adverse Events | 24 Participants |
| Triple-negative Breast Cancer: Crossover | Number of Participants With Adverse Events | 29 Participants |
| BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide | Number of Participants With Adverse Events | 14 Participants |
| BRCA-positive Ovarian Cancer: Cyclophosphamide Alone | Number of Participants With Adverse Events | 4 Participants |
| BRCA-positive Ovarian Cancer: Crossover | Number of Participants With Adverse Events | 6 Participants |
| Non-Hodgkin's: ABT-888 & Cyclophosphamide | Number of Participants With Adverse Events | 0 Participants |
| Non-Hodgkin's: Cyclophosphamide Alone | Number of Participants With Adverse Events | 1 Participants |
Secondary
Number of Participants With Deleterious Mutations in DNA Repair Genes
Gene expression profiling was performed in archival tumor tissue for a panel of 211 genes using deoxyribonucleic acid (DNA) array to determine deleterious mutations (i.e. nonsynonymous mutations at coding regions) of genes. Sequences were mapped to human genome reference hg19. Variants were identified with VarScan, annotated with AVIA, and masked to the exonic or exonic:splicing regions of the 211 interrogated DNA repair genes, with nonsynonymous/frameshift/stop-gain/stop-loss variants that have a population frequency of 1% or less in either 1000G (2014\_04) or the ExomeSequencingProject (ESP6500si\_all) with a minimum variant frequency of 10% and at least 20 reads. Lastly, variants were manually inspected for known platform and mapping errors.
Time frame: Optional tumor biopsies were performed prior to start of treatment (baseline) and 6 months
Population: Patients with sufficient tumor content in archival tissue (defined as ≥70% tumor after macrodissection) were analyzed for genetic alterations in DNA repair genes by whole-exome sequencing.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Number of Participants With Deleterious Mutations in DNA Repair Genes | 28 Participants |
| Triple-negative Breast Cancer: Crossover | Number of Participants With Deleterious Mutations in DNA Repair Genes | 27 Participants |